Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 80 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/22/2008 First Published: 7/1/1999


1.		Phase II/III Study of Standard and Novel Conditioning Therapy and Allogeneic Blood or Marrow Transplantation in Patients With Severe Aplastic Anemia or Hematologic Malignancy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				4 to 70				Other				RPCI-RP-9815 NCI-V99-1527, NCT00003816, RP 98-15


2.		Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				12 to 55				Pharmaceutical / Industry				GC P#02.01.001 NCT00469729

Last Modified: 6/9/2008 First Published: 9/26/2007


3.		Phase II/III Study of Disease-Specific High-Dose Conditioning Regimens Followed by Autologous Stem Cell Transplantation (Single or Tandem) in Patients With Hematologic Malignancies or Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				4 and over				NCI				RPCI-I-72806 I 72806, NCT00536601

Last Modified: 10/21/2008 First Published: 12/23/2003


4.		Phase III Randomized Study of Nonmyeloablative Conditioning Comprising Low-Dose Total Body Irradiation With Versus Without Fludarabine Followed By HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies at Low or Moderate Risk For Graft Rejection

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 75				NCI				FHCRC-1813.00 5666, NCT00075478

Last Modified: 5/23/2007


5.		Phase I/II Study of Epstein Barr Virus Specific Cytotoxic T Lymphocytes from a Normal HLA-Compatible Donor in the Treatment of Patients With Epstein Barr Virus Associated Lymphomas and Other Lymphoproliferative Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Not specified				Other				MSKCC-95024 NCI-V95-0685, NCT00002663

Last Modified: 10/23/2008 First Published: 6/1/2000


6.		Phase I/II Study of Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Followed by Nonmyeloablative Allogeneic PBSC Transplantation in Patients With Refractory or Relapsed Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				65 and under				NCI				FHCRC-1409.00 4903, NCI-G00-1776, NCT00005803

Last Modified: 7/10/2007 First Published: 5/1/2001


7.		Phase I/II Pilot Study of Non-Myeloablative Chemotherapy Followed By Allogeneic Stem Cell Transplantation in Pediatric Patients With Hematopoietic Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				4 to 21				NCI				NCI-01-C-0125F NCT00020592

Last Modified: 10/21/2008 First Published: 8/24/2003


8.		Phase I/II Study of Donor Lymphocyte Infusion in Patients With Persistent, Relapsed, or Progressing Malignancy After Nonmyeloablative Allogeneic Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Any age				NCI				FHCRC-1803.00 5606, NCT00068718


9.		Stem Cell Transplant for Hematologic Diseases and Renal Cell Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				70 and under				Other				H8713 NCT00058825

Last Modified: 5/22/2008 First Published: 12/11/2007


10.		Phase I/II Study of Conditioning Regimen Comprising Clofarabine, Melphalan, and Alemtuzumab Followed By Allogeneic Stem Cell Transplantation in Patients With Advanced Hematologic Malignancies or Other Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				75 and under				NCI				UCCRC-14341B 14341B, UCCRC-05-155, NCT00572546

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute